KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Intangibles (2018 - 2025)

Adaptive Biotechnologies (ADPT) has disclosed Intangibles for 8 consecutive years, with $20.3 million as the latest value for Q4 2025.

  • Quarterly Intangibles changed 0.0% to $20.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $20.3 million through Dec 2025, changed 0.0% year-over-year, with the annual reading at $20.3 million for FY2025, 0.0% changed from the prior year.
  • Intangibles hit $20.3 million in Q4 2025 for Adaptive Biotechnologies, up from $2.2 million in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $20.3 million in Q1 2021 to a low of $2.2 million in Q3 2025.
  • Historically, Intangibles has averaged $11.8 million across 5 years, with a median of $7.5 million in 2022.
  • Biggest five-year swings in Intangibles: skyrocketed 83.42% in 2021 and later plummeted 68.47% in 2023.
  • Year by year, Intangibles stood at $20.3 million in 2021, then changed by 0.0% to $20.3 million in 2022, then changed by 0.0% to $20.3 million in 2023, then changed by 0.0% to $20.3 million in 2024, then changed by 0.0% to $20.3 million in 2025.
  • Business Quant data shows Intangibles for ADPT at $20.3 million in Q4 2025, $2.2 million in Q3 2025, and $2.6 million in Q2 2025.